Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract

Keyphrases

• Ciprofloxacin 100%
• Fluoroquinolones 100%
• Fluoroquinolone Resistance 100%
• Lower Respiratory Tract 100%
• Multidrug-resistant Pathogens 100%
• Clinafloxacin 66%
• Trovafloxacin 50%
• Gatifloxacin 50%
• S. Pneumoniae 50%
• Sparfloxacin 50%
• Moxifloxacin 33%
• Levofloxacin 33%
• Reserpine 33%
• Efflux Pump 33%
• Haemophilus Influenzae 33%
• New Agents 33%
• Active Agent 16%
• Streptococcus Pneumoniae 16%
• Wild Strain 16%
• Resistance Phenotypes 16%
• Pseudomonas Aeruginosa (P. aeruginosa) 16%
• Lower Respiratory Tract Infection 16%
• ParC 16%
• Decreased Susceptibility 16%
• Mutant Strains 16%
• Pseudomonas Aeruginosa Isolates 16%
• Improved Activity 16%
• Haemophilus 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Ciprofloxacin 100%
• Quinolone Derivative 100%
• Infectious Agent 100%
• Respiratory Tract 100%
• Clinafloxacin 66%
• Gatifloxacin 50%
• Trovafloxacin 50%
• Sparfloxacin 50%
• Grepafloxacin 33%
• Moxifloxacin 33%
• Levofloxacin 33%
• Effusion 33%
• Reserpine 33%
• Haemophilus influenzae 33%
• Pseudomonas aeruginosa 33%
• Streptococcus 16%
• Lower Respiratory Tract Infection 16%
• Haemophilus 16%

Immunology and Microbiology

• Infectious Agent 100%
• Pneumococcus 100%
• Lower Respiratory Tract 100%
• Minimum Inhibitory Concentration 100%
• Pseudomonas aeruginosa 50%
• Haemophilus influenzae 50%
• Dilution 25%
• Wild Type 25%
• Type Strain 25%
• Haemophilus 25%